NCT03715998View on ClinicalTrials.gov

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

PHASE2CompletedINTERVENTIONAL

Enrollment

295

Participants

Timeline

Start Date

June 4, 2019

Primary Completion Date

July 8, 2021

Study Completion Date

July 8, 2021

Conditions

Myocardial Infarction

Interventions

DRUG

Ramipril

1 or 2 capsules administered orally, twice daily

DRUG

Firibastat

1 or 2 capsules administered orally, twice daily

Trial Locations (7)

75013

Groupe Hospitalier Pitie-Salpêtrière - Institut de Cardiologie, Paris

Unknown

UKSH Kiel, Kiel

Central Hospital of Hungarian Army, Budapest

Krakowski Szpital Specjalistyczny im. Jana Pawła II, Krakow

NUSCH Bratislava Dpt. of Acute Cardiology, Bratislava

Hospital La Paz,, Madrid

Freeman Hospital Newcastle upon Tyne, Newcastle

All Listed Sponsors

lead

Quantum Genomics SA

INDUSTRY

NCT03715998 - Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction | Biotech Hunter | Biotech Hunter